* Korro Bio Inc KRRO.OQ reported a quarterly adjusted loss
of
$2.43 per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of
$-15.00. The mean expectation of four analysts for the quarter
was for a loss of $2.39 per share. Wall Street expected
results to range from $-2.43 to $-2.36 per share.
* Reported revenue was zero; analysts expected zero.
* Korro Bio Inc's reported EPS for the quarter was a loss of
$2.43.
* The company reported a quarterly loss of $21.83 million.
* Korro Bio Inc shares had risen by 6.2% this quarter and
lost 25.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Korro Bio Inc is
$112.50
This summary was machine generated from LSEG data August 13 at
09:09 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -2.39 -2.43 Missed
Mar. 31 2024 -2.51 -2.44 Beat
Dec. 31 2023 -2.36 -25.65 Missed
Sep. 30 2023 -17.72 -15.50 Beat